Bristol Myers details landmark Abecma multiple myeloma data that ASH turned down

In a tight BCMA CAR-T race, Bristol Myers Squibb has delivered the drug class’s first randomized trial win in multiple myeloma. But the detailed data, recently rejected by the American Society of Hematology for its annual meeting, might simply not matter that much to doctors and the drug’s sales.